Lutathera's First U.S. Copies: Two Paths to Radioligand Generics
The first U.S. copies of a radioligand therapy are here, and they took two different regulatory roads. Curium won approval for Bexlutry through the 505(b)(2) pathway, while Lantheus won final approval for Bravnetsa as an abbreviated new drug application, or ANDA [1][2]. Both copy Novartis's Lutathera, but approval is only the first test: patents, isotope supply and a pending merger will decide how fast competition shows up in clinics.
This explainer walks through what was approved, why the two routes matter, what the reference product's maker argued to the FDA, and what it all means for people who make, test, register and sell radiopharmaceuticals.
What was approved, and when
Lutathera is lutetium Lu 177 dotatate, a peptide receptor radionuclide therapy (PRRT). It pairs a somatostatin analogue with the beta emitter lutetium-177, so the drug binds tumour cells that carry somatostatin receptors and delivers radiation to them [3]. It is used for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, known as GEP-NETs [1].
Curium announced FDA approval of its new drug application for Bexlutry on September 14, 2026 [1]. The company calls it the first radioligand equivalent for adult GEP-NETs and its own first FDA-approved radioligand therapy [1]. Curium said the application relied on published evidence plus targeted bridging data showing a similar biological and chemical profile to Lutathera [1]. It also said the product was available for prescribing [1].
Lantheus took the generic route. The FDA accepted its first-to-file ANDA for the product, then called PNT2003, in January 2024 [3]. Tentative approval followed in March 2026 [3]. On September 22, 2026, Lantheus announced final approval under the brand name Bravnetsa [2]. The company describes it as bioequivalent and therapeutically equivalent to Lutathera [2].
A trade report summed up the timing: Lantheus secured final ANDA approval just days after Curium's 505(b)(2) approval, giving the U.S. two lutetium Lu 177 dotatate follow-ons [4]. The patient group NETRF described Bexlutry as sharing the same active ingredient, dosing, administration and expected efficacy and side effects as an approved lutetium radioligand therapy [5].
Two pathways, two kinds of claims
The difference between the two routes is more than paperwork. An ANDA, filed under section 505(j), must show that the copy is the same as the reference drug in active ingredient, strength, dosage form and route, and that it is bioequivalent. In return, the applicant relies entirely on the FDA's earlier finding that the reference drug is safe and effective. A product approved this way can be rated as therapeutically equivalent, which is what lets pharmacists and formularies treat it as a substitute.
A 505(b)(2) application is a full new drug application. The sponsor can lean on published studies or the FDA's prior findings for another product, but it may also differ from that product in some ways. It must then supply bridging data to show those differences do not change safety or effectiveness. That flexibility is useful when exact sameness is hard to prove, but it usually does not come with an automatic substitution rating.
The two companies' own words track this split. Curium's release refers to a radioligand equivalent approved through 505(b)(2) and supported by bridging data [1]. Lantheus's filing describes Bravnetsa as bioequivalent and therapeutically equivalent [2]. NETRF used the term radioligand equivalent, or RLE, and said the approval drew on the NETTER-1 and ERASMUS studies plus additional data supporting Bexlutry's application [5].
The labels also show a familiar generic detail. Bexlutry's prescribing information leaves out the pediatric information approved for Lutathera, because of marketing exclusivity held by Advanced Accelerator Applications USA, the Novartis unit that sells Lutathera [1][6]. Curium's label states that safety and effectiveness have not been established in patients under 12 [1].
Side by side
| Item | Bexlutry (Curium) | Bravnetsa (Lantheus) |
|---|---|---|
| Pathway | 505(b)(2) new drug application [1] | ANDA, accepted as first to file in January 2024 [3] |
| Key approval date | Announced September 14, 2026 [1] | Tentative approval March 2026; final approval announced September 22, 2026 [3][2] |
| Basis | Published evidence plus targeted bridging data [1] | Bioequivalent and therapeutically equivalent to Lutathera [2] |
| Launch status | Available for prescribing, per Curium [1] | No public launch date set [2] |
| Manufacturing | Calls itself the only vertically integrated lutetium-based NET therapy maker [1] | Depends on partner POINT for commercial capacity [2] |
The sameness fight before approval
Radiopharmaceuticals are hard to copy because their strength is not a simple milligram count. In April 2024, Advanced Accelerator Applications USA filed a citizen petition asking the FDA to set conditions for any ANDA or 505(b)(2) application that relied on Lutathera [6].
The petition argued that volumetric activity, the radioactivity per millilitre, was not on its own an adequate measure of Lutathera's strength [6]. It asked the FDA to require data showing the same total activity at injection and the same specific activity at calibration [6]. Specific activity is the ratio of radioactivity to the total mass of the ligand, so it captures how much of the peptide actually carries the isotope.
The company's reasoning was biological. Labelled and unlabelled ligand compete for the same receptors on the cell surface, the petition said [6]. A copy with matching radioactivity could still carry a different total mass of ligand, or a different mix of labelled and unlabelled molecules [6]. The petition argued those differences could lead to clinically meaningful differences, and that without proof of sameness, additional clinical studies would be needed [6].
The petition also pointed to a 2019 draft product-specific guidance that had recommended a bioequivalence waiver based on formulation sameness [6]. It argued that such a waiver should not apply unless ligand mass and the labelled share also match [6]. The sources reviewed here do not include the FDA's written response. What is clear is the outcome: the agency approved one copy as an ANDA and another as a 505(b)(2) product [1][2].
For developers, the lesson is that analytical characterization is the core of a radiopharmaceutical copy. Specific activity, ligand mass and fill rules are not side issues. They are the evidence.
What the evidence shows
The clinical case for lutetium Lu 177 dotatate rests on the NETTER-1 phase 3 trial. Bexlutry draws on NETTER-1 rather than repeating it [1][5], and Bravnetsa, as an ANDA, relies on the FDA's findings for Lutathera [2]. NETTER-1 randomized 231 patients with progressive, somatostatin receptor-positive midgut tumours to the radioligand plus octreotide LAR or to high-dose octreotide LAR alone [3]. At 20 months, progression-free survival was 65.2% with the radioligand and 10.8% in the control arm [3]. Response rates were 18% and 3% [3].
The final analysis did not show a statistically significant gain in median overall survival, though the numeric difference was 11.7 months [3]. That nuance matters for payers and for anyone modelling uptake. The copies inherit the same evidence base, with its strengths and its limits.
The safety profile carries over too. Curium's label warns about radiation exposure, myelosuppression, myelodysplastic syndrome and leukemia, kidney and liver toxicity, and infertility [1]. In NETTER-1, myelodysplastic syndrome occurred in 2.3% of patients receiving the radioligand, with a median follow-up of 76 months [1].
The commercial data show what is at stake. Novartis reported Lutathera sales of USD 219 million in the third quarter of 2026, up 3% at constant currency [7]. For the first nine months, sales were USD 655 million, up 6% [7]. Pluvicto, Novartis's PSMA-targeted radioligand for prostate cancer, grew much faster: USD 674 million in the quarter, up 20%, and USD 1,967 million over nine months, up 41% [7]. Novartis's results release did not discuss Lutathera competition [7].
Put those numbers together and a picture forms. Lutathera is a mature, slower-growing franchise worth more than USD 650 million in nine months [7]. That is a large enough target to justify two separate copy programs, but its growth is already modest before any competition arrives.
Patents, launch timing and the merger
Approval does not equal launch. Lantheus says it has not set a public launch date for Bravnetsa [2]. Its quarterly filing ties timing to the Hatch-Waxman legal proceedings, including a pending appeal, as well as manufacturing and commercial readiness [2]. Hatch-Waxman is the 1984 law that created the modern U.S. generic system and its patent challenge rules.
According to Lantheus, the U.S. District Court ruled that all the patents Advanced Accelerator Applications asserted were invalid [2]. The patent holder appealed. On July 2, 2026, the U.S. Court of Appeals for the Federal Circuit denied its motion to stay a Lantheus launch [2]. Oral argument is scheduled for December 14, 2026 [2]. Earlier, Lantheus had said it expected final approval and commercial availability after Lutathera's exclusivity period ended in June 2026 [3].
The deal terms behind Bravnetsa are also public. Lantheus licensed the product from POINT Biopharma in November 2022 [2]. It owes POINT a USD 10.0 million milestone on final approval and royalties of 15% of net sales [2]. It also relies on POINT to build commercial capacity and to manufacture the product [2].
Then there is the merger. On August 3, 2026, Lantheus agreed to be acquired by Curium for USD 102.50 per share in cash plus contingent value rights worth up to USD 12.00 per share [8]. The companies put the total value at up to about USD 8 billion [8]. Lantheus stockholders adopted the merger agreement on October 14, 2026 [2]. Closing is still expected in the first half of 2027, subject to regulatory approvals [2][8].
The merger material says Lantheus is focusing mainly on radiodiagnostics and pursuing value-maximizing alternatives for its radiotherapeutic assets [8]. It refers to the product only as PNT2003, then tentatively approved, and does not say what will happen to it [8]. If the deal closes with Bravnetsa still inside Lantheus, both approved Lutathera copies would sit under one parent. That would change the competitive math that two rival copies usually bring. Watch how antitrust review and any asset sale address this.
Supply is the real constraint
Conventional generics can flood a market within months. Radioligands may not. The Generics Bulletin framed the launches as a real-world test of whether radiopharmaceutical supply complexity can soften the price erosion seen with ordinary generics [4].
The reasons are physical. Lutetium-177 has a half-life of about 6.6 days, so the product loses activity every day it sits [6]. The Lutathera petition described a single-dose vial whose fill volume depends on the time between calibration and injection [6]. A copy has to match that logistics model, not just the chemistry.
That is why manufacturing claims feature so heavily in both companies' messaging. Curium calls itself the only vertically integrated maker of a lutetium-based NET therapy and stresses reliable supply [1]. It lists 80 manufacturing sites and a presence in more than 70 countries [8]. Lantheus, by contrast, flags its dependence on a partner for capacity as a risk [2]. NETRF noted that more options can support patient access, provider choice, manufacturing capacity and supply reliability [5].
What it means for people in the industry
Regulatory affairs. Both doors are now open for radioligand copies. Teams planning follow-ons to other radioligands now have two real precedents to study. The choice between an ANDA and a 505(b)(2) application will turn on how confidently a sponsor can show sameness in specific activity, ligand mass and fill [6].
CMC and quality. Chemistry, manufacturing and controls work is where these programs live or die. Expect more demand for people who can characterize labelled and unlabelled ligand and measure total ligand mass [6]. Validating release methods and defending comparability to a reference product will matter just as much. Quality teams will need release testing that holds up within a short shelf life.
Manufacturing and supply chain. Isotope sourcing, dose dispensing and time-critical distribution are now competitive levers. Companies with their own networks may win early share, while those that rely on partners carry execution risk [1][2].
Business development and legal. The Bravnetsa licence shows the shape of these deals: a USD 10.0 million upfront payment, a USD 10.0 million approval milestone, a 15% royalty and up to USD 275.0 million in sales milestones [2]. Patent litigation remains a gating item, and the December appeal hearing is the next date to watch [2].
Commercial and market access. With Lutathera growing 3% in the latest quarter, the copies enter a mature market [7]. Pricing, contracting with treatment centres and supply reliability will matter more than clinical claims, since the evidence base is shared [1][5].
For broader context on deals and approvals as they happen, follow PharmoniQ news.
Key takeaways
- The U.S. now has two approved copies of Lutathera: Curium's Bexlutry through 505(b)(2) and Lantheus's Bravnetsa through an ANDA [1][2].
- The routes differ: Bravnetsa claims therapeutic equivalence, while Bexlutry relied on published evidence and bridging data [1][2].
- Novartis's unit argued in 2024 that copies must match total activity and specific activity, not just radioactivity per millilitre [6].
- Lutathera sold USD 655 million in the first nine months of 2026, growing 6% at constant currency [7].
- Bravnetsa has no public launch date, and a Federal Circuit hearing on the patent appeal is set for December 14, 2026 [2].
- Curium's pending acquisition of Lantheus, expected to close in the first half of 2027, could put both copies under one owner [8].
- A short half-life and single-patient doses could slow the price erosion typical of generics, a question the Generics Bulletin raised [6][4].
References
- Curium announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs. Curium, Sep 16, 2026.
- Lantheus Holdings, Inc. Form 10-Q for the quarter ended September 30, 2026. U.S. Securities and Exchange Commission, Nov 2026.
- FDA Issues Tentative Approval to Lu 177 Dotatate Radioequivalent for GEP-NETs. Targeted Oncology, Mar 3, 2026.
- Two Lutathera Rivals Put Novartis' Radioligand Stronghold To The Test. Generics Bulletin (Citeline), Sep 23, 2026.
- FDA Approves New Radioligand Therapy for GEP-NETs. Neuroendocrine Tumor Research Foundation, Sep 21, 2026.
- Citizen petition on applications that rely on Lutathera (FDA-2024-P-1871). Advanced Accelerator Applications USA, via Regulations.gov, Apr 12, 2024.
- Novartis Q3 2026 media release. Novartis, Oct 27, 2026.
- Lantheus Announces Definitive Agreement to Merge with Curium. Lantheus, Aug 3, 2026.
Check Your Supplement Interactions
Use our AI-powered interaction checker to analyze your full supplement stack for safety, timing conflicts, and synergies.
PharmoniQ Editorial
Expert pharmaceutical content powered by AI and curated by industry professionals. Our team combines pharmaceutical science, clinical research, and data analytics to deliver accurate, evidence-based supplement information.
Building a Supplement Stack?
Get personalized workout plans that pair perfectly with your supplements. FitFixLife helps you train smarter.
Visit FitFixLife →Related Articles
PDUFA VIII: What the FDA's Next User Fee Deal Changes
The proposed PDUFA VIII deal keeps FDA review clocks but adds a first-cycle audit, facility meetings and fee cuts for U.S. phase 1 trials. Congress must act by 2027.
Bayesian Trials at the FDA: What the Draft Guidance Asks
The FDA's draft guidance lets sponsors borrow earlier data in pivotal trials using Bayesian statistics. Here is what it requires and where the debate sits.
Canada's Drug Reliance Order: What It Changes for Sponsors
Health Canada can now rely on trusted foreign regulators for parts of some drug reviews. What the Order covers, how it compares, and what sponsors should do.
Comments (0)
Note: This article is general information, not medical, legal, regulatory or investment advice. It was written with AI assistance. Facts come from the sources in the reference list. Check the original source before relying on any detail.